Results of the dinutuximab beta, bevacizumab, irinotecan and topotecan randomisations of the beacon-neuroblastoma Phase 2 trial by itcc and siopen
Moreno, L. Weston, R. Owens, C. Gray, J. Barone, G. Valteau-Couanet, D. Simon, A. R. S. Makin, Guy Vaidya, S. Gambart, M.
Moreno, L.
Weston, R.
Owens, C.
Gray, J.
Barone, G.
Valteau-Couanet, D.
Simon, A. R. S.
Makin, Guy
Vaidya, S.
Gambart, M.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Moreno L, Weston R, Owens C, Gray J, Barone G, Valteau-Couanet D, et al. Results of the Dinutuximab Beta, Bevacizumab, Irinotecan and Topotecan Randomisations of the Beacon-Neuroblastoma Phase 2 Trial by Itcc and Siopen. Pediatric blood & cancer. 2022 Nov;69. PubMed PMID: WOS:000859203900215.